R1 is selected from hydrogen, cyano, C1-3alogenoalkinyl, SO2NRbRc, C0-2alkyl(O)NRbRc, C1-4alkylNBbRc, SO2Ri, C(O)ORa, CH(OH)Rj and C(O)Rj; R2 and R4 are independently selected from hydrogen, halogeno, cyano, NO2, C1-4alkyl, C1-3ahalogenoalkyl, ORa, C(O)NRbRc, SO2Ri, and C(O)ORa; or R1 and R2 together with atoms, to which they are bound, are bound with formation of 5- or 6-member heterocyclic ring, which contains one S, any of the hydrogen atoms of group CH2 in said heterocyclic ring can be substituted by oxo, hydroxy, and sulphur atom in said heterocyclic ring is probably oxydised to -SO2-; R3 and R5 represent hydrogen; R6 represents tetrahydropyran; R7 is selected from hydrogen, C1-3alkyl, cyano and C1-3halogenoalkyl; R8 represents hydrogen; Ra is selected from C1-3alkyl and C1-3halogenoakryl. Other radicals are given in formula of invention.;EFFECT: compounds can be applied in manufacturing medication for prevention and/or treatment of predemential states, moderate cognitive failure and type II diabetes, Alzheimer's disease and Parkinson disease, as well as bone-associated malfunctions.;40 cl, 3 dwg, 1 tbl, 122 ex"/>
公开/公告号RU2433128C2
专利类型
公开/公告日2011-11-10
原文格式PDF
申请/专利权人 ASTRAZENEKA AB;
申请/专利号RU20080110910
发明设计人 ANDERSSON LARS (SE);ARZEL EHRVAN (SE);BERG STEFAN (SE);BARROUZ DZHEREMI (SE);KHELLBERG SVEN (SE);KHUEHRTA FERNANDO (SE);PEDERSEN TORBEN (SE);REJN TOBIAS (SE);ROTTICHCHI DIDE (SE);STAAF KARIN (SE);TUREK DOMINIKA (SE);
申请日2006-10-02
分类号C07D405/14;A61K31/506;A61K31/5377;A61P25/16;A61P25/28;A61P3/10;
国家 RU
入库时间 2022-08-21 17:48:11